Novo Nordisk Q1 2026 Earnings: What They Reveal About GLP-1 Supply

Earnings calls aren't exciting. But for GLP-1 patients, they're the most reliable signal of where supply, pricing, and availability are headed. Here's what Novo's latest numbers actually tell us.

Pharmaceutical earnings reports are dense with financial jargon, but for GLP-1 patients, they contain critically useful information that doesn't appear anywhere else: real manufacturing capacity data, supply forecasts, pricing strategy signals, and competitive positioning. When Novo Nordisk's CEO tells Wall Street analysts what's coming, he's giving patients a roadmap — even if that's not the intended audience.

Here's what the most recent Novo Nordisk earnings data tells us about the GLP-1 market in practical terms.

The Supply Picture: Shortage Is Over, Capacity Is Growing

Novo Nordisk has invested heavily in manufacturing capacity since the shortage crisis. The company committed approximately $6 billion in capital expenditure for production expansion between 2024 and 2026, including new filling and finishing lines, expanded API (active pharmaceutical ingredient) synthesis, and new manufacturing facilities.

The practical impact: Wegovy and Ozempic are no longer on the FDA shortage list and are generally available at retail pharmacies. Starter doses, which were the most constrained during the shortage, are now routinely in stock. The supply-side constraints that drove millions of patients to compounding pharmacies between 2022 and 2025 have been materially resolved.

The Pricing Strategy: Defensive Moves

Novo's earnings commentary reveals a company responding to two competitive threats simultaneously: compounding pharmacies on the low end and Eli Lilly's tirzepatide on the high end.

Against compounding: Novo launched its NovoCare self-pay savings program, offering Wegovy at $349–$499/month without insurance. This directly targets the $200–$400/month compounded market. The company has also pursued regulatory pressure through FDA complaints about compounders using Novo brand names.

Against Eli Lilly: Tirzepatide (Mounjaro/Zepbound) has been taking market share from semaglutide, particularly in the weight-loss segment. The SURMOUNT-5 head-to-head trial showed tirzepatide producing 20.2% weight loss vs. semaglutide's 13.7%. Novo's response has been threefold: expanding indications (MASH, cardiovascular, OSA), developing oral Wegovy (25mg), and accelerating next-generation pipeline (CagriSema, amycretin).

What Patients Should Take Away

1. Brand-name Wegovy is more accessible than ever

Between improved supply, self-pay pricing programs, and expanded insurance coverage (Wegovy now has a cardiovascular indication, which makes insurance approval easier), brand-name semaglutide is a realistic option for more patients than at any point since the shortage began.

2. Pricing pressure will continue downward

Competition from Lilly, compounders, and the inevitable arrival of biosimilar semaglutide (expected within 2–3 years as patents expire) means prices will continue to decline. Patients who found GLP-1 therapy unaffordable two years ago should re-evaluate — the economics have shifted significantly.

3. New formulations are coming

Oral Wegovy is the near-term addition. Longer-term, Novo's pipeline includes CagriSema (semaglutide + cagrilintide, an amylin analog) which showed approximately 25% weight loss in Phase 3 trials — substantially more than semaglutide alone. Patients starting GLP-1 therapy now should be aware that more effective options are likely within 1–2 years.

4. The compounded market is being squeezed from both sides

Novo's aggressive pricing, legal action, and regulatory pressure — combined with improved brand-name supply — are designed to reduce the economic case for compounding. Patients currently on compounded semaglutide should periodically re-evaluate whether brand-name self-pay options have become competitive with their current costs.

Access Options: Brand-Name and Compounded